Barrington Research Maintains Outperform on Surmodics, Maintains $71 Price Target
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on Surmodics (NASDAQ:SRDX), with a price target of $71.
May 02, 2024 | 6:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surmodics maintains its Outperform rating by Barrington Research with a steady price target of $71, indicating a positive outlook on the stock.
The reaffirmation of the Outperform rating and the maintenance of a $71 price target by Barrington Research suggests a strong confidence in Surmodics' potential for growth or positive performance in the near term. This analyst endorsement can positively influence investor sentiment and potentially lead to an increase in stock price, especially if the market aligns with the analyst's outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100